Pictet Asset Management
AXSM icon

Pictet Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Pictet Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104M Buy
426,527
+10,544
+3% +$2.29M 0.1% 218
2026
Q1 		$70.3M Sell
415,983
-20,080
-5% -$3.47M 0.07% 259
2025
Q4 		$79.6M Buy
436,063
+73,925
+20% +$10.3M 0.08% 249
2025
Q3 		$44M Sell
362,138
-49,712
-12% -$5.6M 0.04% 349
2025
Q2 		$43M Buy
411,850
+78,645
+24% +$8.33M 0.04% 344
2025
Q1 		$38.9M Buy
333,205
+328,527
+7,023% +$37.4M 0.04% 355
2024
Q4 		$396K Buy
4,678
+761
+19% +$70K ﹤0.01% 1490
2024
Q3 		$352K Sell
3,917
-375
-9% -$32.7K ﹤0.01% 1514
2024
Q2 		$346K Sell
4,292
-348,074
-99% -$25.8M ﹤0.01% 1450
2024
Q1 		$28.1M Sell
352,366
-346,566
-50% -$29.1M 0.03% 413
2023
Q4 		$55.6M Buy
698,932
+52,503
+8% +$3.51M 0.06% 285
2023
Q3 		$45.2M Buy
+646,429
New +$48.3M 0.06% 305

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pictet Asset Management's AXSM Position: Q2 2026 in Review

Pictet Asset Management increased its Axsome Therapeutics (AXSM) stake by 2.5% in Q2 2026, buying an estimated $2.29M and bringing the position to 426,527 shares worth $104M. The position accounts for 0.1% of the portfolio, ranked #218.

Pictet Asset Management first reported a position in AXSM in Q3 2023 and has held it in 12 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Pictet Asset Management held 426,527 shares of Axsome Therapeutics worth $104M as of Q2 2026.
  • Pictet Asset Management bought 10,544 Axsome Therapeutics shares in Q2 2026, an estimated $2.29M.
  • Axsome Therapeutics made up 0.1% of Pictet Asset Management's portfolio in Q2 2026, its #218 holding.
  • Pictet Asset Management first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.